{"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"37"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed or refractory PTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"BG000","title":"PTCL: E7777 9 mcg/kg/Day"},{"description":"Participants with CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"BG001","title":"CTCL: E7777 9 mcg/kg/Day"},{"description":"Participant with extranodal NK/T-cell lymphoma received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"BG002","title":"Other: E7777 9 mcg/kg/Day"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.16","value":"66.7"},{"groupId":"BG001","spread":"15.09","value":"55.3"},{"groupId":"BG002","value":"70.0"},{"groupId":"BG003","spread":"13.63","value":"60.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"12"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"37"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"37"}]}],"title":"Japanese"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The safety analysis set was defined as a group of participants who received at least 1 dose of the study drug with at least 1 evaluable postbaseline safety data."}